Update on the seroprevalence rates to SARS-CoV-2 among blood bank donors and healthcare workers at KHCC: Establishing a COVID-19-Convalescent plasma biobank.
- مجال مشروع البحث–الرئيسي
- العلوم الطبية والصحية
- مجال مشروع البحث–الثانوي
- الامراض المزمنة
- المؤسسة العلمية
- مركز الحسين للسرطان
- المحافظة
- عمان
- قيمة الدعم
- JD19983
- سنة الدعم
- 2020
- حالة المشروع
- منتهي مع النشر
- البحث منشور
- (1) Souan, L., Sughayer, M. A., Abualhour, M. M., Siag, M., Al-Badr, S., & Al-Atrash, T. (2022). Comparison of the Immunogenicity and Protective Efficacy of Various SARS-CoV-2 Vaccines among Healthcare Workers: Are Our White Coat Armies Protected?. Vaccines, 10(5), 642.
(2) Sughayer, M. A., Souan, L., Alhowr, M. A., Al Rimawi, D., Siag, M., Albadr, S., ... & Al Atrash, T. (2022). Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. Vaccine, 40(20), 2841-2847.
(3)Souan, L. Sughayer, MA. Abu Alhowr, MM. Establishing the first COVID-19 convalescent plasma biobank in Jordan. Biopreservation and Biobanking, 2022. In press
- ملخص عن مشروع البحث
- (1) Background: The effective immunization of healthcare workers (HCWs) plays a vital role in preventing the spread of SARS-CoV-2 infection during the coronavirus disease 2019 (COVID-19) pandemic. There is limited data on the immune response to vaccination among HCWs. We aim to determine seroprevalence rates and neutralizing IgG antibody response to various immunizations among HCWs. Methods: This study was conducted between July and September 2021, in which blood samples were obtained from HCWs and SARS-CoV-2 IgG neutralizing antibodies were measured. Data regarding vaccination status with Pfizer/BioNTech, Sinopharm, or AstraZeneca vaccines, occupation, and prior COVID-19 infection were analyzed. Results: COVID-19 infection post-vaccination was associated with higher mean antibody titers, regardless of vaccine type. Pfizer/BioNTech vaccination produced higher mean antibody titers for HCWs with prior COVID-19 infection (p < 0.00001) than other types of vaccines. Although 96% of HCWs were vaccinated, 3% were seronegative. For HCWs who were seropositive, there were no significant differences between the mean antibody titers when comparing occupations and blood indices. Conclusion: Awareness of the immunity status of HCWs is key to protecting this important group against SARS-CoV-2, especially those without prior COVID-19 infection. Further public health efforts regarding booster vaccination for HCWs are crucial to provide necessary antibody protection.
https://www.mdpi.com/2076-393X/10/5/642
(2) Background and objectives:Little is known about the efficacy and durability of anti-RBD IgG antibodies induced by certain SARS-CoV-2 vaccines. It has been shown that neutralizing antibodies are associated with the protection against re-infection. This study aims to compare the mean titers, duration, and efficacy of generating protective anti-RBD IgG antibody response among recipients of Pfizer/BioNTech, AstraZeneca, Sputnik V, Johnson & Johnson, Moderna, and Sinopharm COVID-19 vaccines. In addition, we aimed to compare the susceptibility of getting COVID-19 breakthrough infections after various types of vaccines.
Materials and methods:Samples from 2065 blood bank donors and healthcare workers at King Hussein Cancer Center (KHCC) were collected between February and September 2021. Anti-Spike/RBD IgG levels were measured using Chemiluminescent microparticle-immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA).
Results: The mean titer of anti-RBD IgG levels was significantly diverse among different types of vaccines. The highest titer level was seen in participants who took a third booster vaccine shot, followed by Pfizer/BioNTech, AstraZeneca, and Sinopharm vaccine. The mean titer levels of anti-RBD IgG antibodies in the Pfizer vaccinated group was the highest after vaccination but started to drop after 60 days from vaccination unlike AstraZeneca and Sinopharm vaccine-induced antibodies where the mean titers continued to be stable until 120 days but their levels were significantly lower. Most of the breakthrough infections were among the Sinopharm vaccinated group and these breakthroughs happened at random times for the three main types of vaccines. Conclusions:Our data demonstrate that the mean-titer of anti-RBD IgG levels drop after four months which is the best time to take the additional booster shot from a more potent vaccine type such as mRNA vaccines that might be needed in Jordan and worldwide.
https://www.sciencedirect.com/science/article/pii/S0264410X22003875
(3) in press
-
الاسم الكامل للباحث الرئيسي
د.لينا صوان
الجنس
انثى
-
الباحث المشارك الأول
د. ماهر الصغير
الجنس
ذكر
المشاريع ذات صلة